Clinical trial
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in…
NCT00441376 · Imunon, Industry · Completed
Key facts
| NCT number | NCT00441376 |
|---|---|
| Title | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver |
| Official title | A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver |
| Lead sponsor | Imunon, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma, Liver Neoplasms |
| Intervention type | Drug |
| Interventions | ThermoDox |
| Enrollment | 30 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Feb 28, 2007 |
| Last update posted | Feb 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: